Plasma p-tau217 Clocks Estimate Timing of Alzheimer Symptom Onset

This work demonstrates that a single blood-based %p-tau217 measurement can estimate not only whether but approximately when a cognitively unimpaired person will develop symptomatic Alzheimer disease, with implications for how pharmacists interpret emerging blood biomarker tests and screen for anti-amyloid therapy candidates.

plasma p-tau217%p-tau217blood-based biomarkersAlzheimer diseasepreclinical ADclock modelsTIRASILAPrecivityAD2Fujirebio LumipulseADNIKnight ADRCbiomarker stagingobservational study Neurology / Neuropharmacology

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Petersen KK, Milà-Alomà M, Li Y, Du L, Xiong C, Tosun D, Saef B, Saad ZS, Du-Cuny L, Coomaraswamy J, Mordashova Y, Rubel CE, Meyers EA, Shaw LM, Dage JL, Ashton NJ, Zetterberg H, Ferber K, Triana-Baltzer G, Baratta M, Rosenbaugh EG, Cruchaga C, McDade E, Holtzman DM, Morris JC, Sabandal JM, Bateman RJ, Bannon AW, Potter WZ, Schindler SE, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team

Citation: Petersen KK, Milà-Alomà M, Li Y, et al. Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks. Nature medicine. 2026;32(3):1085-1094. doi:10.1038/s41591-026-04206-y

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →